IRIS
MANCARDI, GIOVANNI LUIGI
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 42.376
Totale 42.376
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 42.376
Totale 42.376
Salva come PNG Salva come JPEG
Città #
Genova 35.457
Rapallo 4.076
Genoa 2.763
Bordighera 80
Totale 42.376
Salva come PNG Salva come JPEG
Nome #
Composite MRI measures and short-term disability in patients with clinically isolated syndrome suggestive of MS 185
Safety and tolerability of fingolimod in patients with relapsing-remitting multiple sclerosis: results of an open-label clinical trial in Italy 182
A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. 165
An updated Italian normative dataset for the Stroop color word test (SCWT) 159
Association of melanoma and natalizumab therapy in the Italian MS population: a second case report. 158
Early switch to fingolimod may decrease the risk of disease recurrence after natalizumab interruption 153
A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. 153
Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. 151
Neural correlates of ankle movements during different motor tasks: A feasibility study 150
Hereditary motor and sensory neuropathy with myelin outfolding: clinical, genetic and neuropathological study of three cases 149
Basal ganglia are active during motor performance recovery after a demanding motor task. 149
Repeated courses of granulocyte colony-stimulating factor in amyotrophic lateral sclerosis: clinical and biological results from a prospective multicenter study. 149
Cord cross-sectional area at foramen magnum as a correlate of disability in amyotrophic lateral sclerosis 149
Mechanisms of the adaptive immune response inside the central nervous system during inflammatory and autoimmune diseases. 146
Fast course ALS presenting with vocal cord paralysis: clinical features, bioinformatic and modelling analysis of the novel SOD1 Gly147Ser mutation. 146
Experimental Charcot-Marie-Tooth type 1A: A cDNA microarrays analysis 145
Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results. 145
Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. 145
Urinary JCV-DNA Testing during Natalizumab Treatment May Increase Accuracy of PML Risk Stratification. 144
Reliability of clinical outcome measures in Charcot-Marie-Tooth disease. 144
The long-term effect of AHSCT on MRI measures of MS evolution: a five-year follow-up study. 144
Bovine spongiform encephalopathy and Creutzfeldt-Jakob disease: facts and uncertainties underlying the causal link between animal and human diseases 143
OXCARBAZEPINE FOR TREATING PAROXYSMAL PAINFUL SYMPTOMS IN MULTIPLE SCLEROSIS: A PILOT STUDY. 143
Evidence for aerobic ATP synthesis in isolated myelin vesicles 143
Retinal nerve fibre layer measurements and optic nerve head analysis in multiple sclerosis patients. 142
Mesenchymal stem cells effectively modulate pathogenic immune response in experimental autoimmune encephalomyelitis. 141
Alpha-lipoic acid is effective in prevention and treatment of experimental autoimmune encephalomyelitis. 141
Phase III dose-comparison study of glatiramer acetate for multiple sclerosis. 140
Autologous stem cell transplantation as rescue therapy in malignant forms of multiple sclerosis. 140
Three years of experience: the Italian registry and safety data update 140
Recapitulation of B cell differentiation in the central nervous system of patients with multiple sclerosis. 140
A normative study of the Italian printed word version of the free and cued selective reminding test 139
In vitro VLA-4 blockade results in an impaired NK cell-mediated immune surveillance against melanoma 139
Autologous haematopoietic stem cell transplantation for secondary progressive multiple sclerosis: an exploratory cost-effectiveness analysis. 138
Hereditary motor and sensory neuropathy with deafness, mental retardation and absence of large myelinated fibers. 138
Growing Region Segmentation Software (GRES) for quantitative magnetic resonance imaging of multiple sclerosis: intra- and inter-observer agreement variability: a comparison with manual contouring method. 138
The molecular signature of therapeutic mesenchymal stem cells exposes the architecture of the hematopoietic stem cell niche synapse. 138
Relapses after treatment with rituximab in a patient with multiple sclerosis and anti myelin-associated glycoprotein polyneuropathy. 136
Clinical epidemiology of ALS in Liguria, Italy. 136
Clinical characteristics of patients with familial amyotrophic lateral sclerosis carrying the pathogenic GGGGCC hexanucleotide repeat expansion of C9ORF72. 136
Development and validation of a patient self-assessed questionnaire on satisfaction with communication of the multiple sclerosis diagnosis. 136
Dysimmune mononeuropathies: A diagnosis not to be missed 136
The prevalence of pain in multiple sclerosis: a multicenter cross-sectional study. 135
Granulocyte-macrophage colony-stimulating factor activity in cerebrospinal fluid 135
Neurological research in Italy in 2003 and 2004. 134
Anxiety and depression in multiple sclerosis patients around diagnosis. 134
Intense immunosuppression followed by autologous stem cell transplantation in severe multiple sclerosis. 134
Stem cells for multiple sclerosis: promises and reality. 133
Direct immunofluorescence in sural nerve biopsies. 133
17p11.2 duplication is a common finding in sporadic cases of charcot-marie-tooth type 1 133
Underexpression of messenger RNA for peripheral myelin protein 22 in hereditary neuropathy with liability to pressure palsies 132
Human mesenchymal stem cells promote survival of T cells in a quiescent state. 132
Mycophenolate mofetil in dysimmune neuropathies: a preliminary study. 132
Early abnormalities in sciatic nerve function and structure in a rat model of Charcot-Marie-Tooth type 1A disease. 130
Acute disseminated encephalomyelitis with severe neurological outcomes following virosomal seasonal influenza vaccine 130
ATXN2 is a modifier of phenotype in ALS patients of Sardinian ancestry. 130
Autologous hematopoietic stem cell transplantation in multiple sclerosis: A phase II trial. 129
Clinical epidemiology of amyotrophic lateral sclerosis in Liguria, Italy: An update of LIGALS register 129
Autologous haematopoietic stem cell transplantation with an intermediate intensity conditioning regimen in multiple sclerosis: the Italian multi-centre experience. 129
Selective impairments of motor sequence learning in multiple sclerosis patients with minimal disability 128
The prevalence of multiple sclerosis in the north-west Italian province of Genoa. 127
A patient with multiple sclerosis and Down's syndrome with a rare paroxysmal symptom at onset. 126
Autologous hematopoietic stem cell transplantation for autoimmune diseases: an observational study on 12 years' experience from the European Group for Blood and Marrow Transplantation Working Party on Autoimmune Diseases. 126
Neural correlates of lower limbs proprioception: An fMRI study of foot position matching 126
Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone. 126
Upper limb motor training based on task-oriented exercises induces functional brain reorganization in patients with multiple sclerosis 126
T137A variant is a pathogenetic SOD1 mutation associated with a slowly progressive ALS phenotype. 125
Brain stroke imaging by means of microwave tomography: Quantitative inversion procedure, configuration set up, and preliminary experimental results 125
Different MRI patterns in MS worsening after stopping fingolimod 125
Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation. 125
Multiple sclerosis: hyperintense dentate nucleus on unenhanced T1-weighted MR images is associated with the secondary progressive subtype 124
A prospective study of acute idiopathic neuropathy II antecedent events. 124
Cranial MRI in ataxia-telangiectasia. 124
The Multiple Sclerosis Knowledge Questionnaire: a self-administered instrument for recently diagnosed patients. 124
Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: a meta-analytic approach 123
GFAP expression of human Schwann cells in tissue culture. 123
Charcot-Marie-Tooth (CMT) 1a duplication at 17p11.2 in Italian families. 123
Progressive sensory-motor polyneuropathy with tomaculous changes is associated to 17p11.2 deletion. 123
HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR MULTIPLE SCLEROSIS: COLLABORATION OF THE CIBMTR AND EBMT TO FACILITATE INTERNATIONAL CLINICAL STUDIES 123
Impairment of PMP22 transgenic Schwann cells differentiation in culture: implications for Charcot-Marie-Tooth type 1A disease. 122
An Italian family with Ala-47 transthyretin mutation associated with cardiomyopathy and polyneuropathy. 122
A prospective, randomized, controlled trial of autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: a position paper. 122
A restricted T cell response to myelin basic protein (MBP) is stable in multiple sclerosis (MS) patients. 122
Mesenchymal stem cells for multiple sclerosis: does neural differentiation really matter? 122
'Apraxia' of eye opening in idiopathic Parkinson's disease. 121
PMP22 transgenic dorsal root ganglia cultures show myelin abnormalities similar to those of human CMT1A. 121
A major influence of the T cell receptor repertoire as compared to antigen processing-presentation in the selection of myelin basic protein epitopes in multiple sclerosis. 121
Early degeneration of the cerebellar cortex, particularly the granular cells. 121
The D355V mutation decreases EGR2 binding to an element within the Cx32 promoter. 121
Insulin treatment enhances expression of IGF-I in sural nerves of diabetic patients. 121
Long-term Outcomes After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis 121
Accumulation of clonally-related B lymphocytes in the cerebrospinal fluid of multiple sclerosis patients 120
LOSS OF EPIDERMAL GROWTH FACTOR REGULATION BY COBALAMIN IN MULTIPLE SCLEROSIS 120
Rituximab in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a report of 13 cases and review of the literature. 120
Schwann cell expression of HLA-DR antigen in peripheral neuropathies. 120
Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. 120
The results of two multicenter, open-label studies assessing efficacy, tolerability and safety of protiramer, a high molecular weight synthetic copolymeric mixture, in patients with relapsing-remitting multiple sclerosis. 120
Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. 120
An engineered glove for investigating the neural correlates of finger movements using functional magnetic resonance imaging 120
Autologous hemopoietic stem cell transplantation for multiple sclerosis: Is it worthwile? 119
Totale 13.410
Salva come PNG Salva come JPEG
Categoria #
all - tutte 104.578
article - articoli 96.593
book - libri 425
conference - conferenze 6.871
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 689
Totale 209.156
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20193.030 0 0 0 0 0 0 0 0 0 611 1.315 1.104
2019/202013.269 559 449 583 917 1.221 1.385 2.166 931 1.236 2.041 1.244 537
2020/20213.506 275 315 396 372 179 256 196 348 291 384 233 261
2021/20225.493 165 399 656 695 170 292 287 1.250 217 494 152 716
2022/20234.881 491 396 58 467 803 858 20 370 854 27 467 70
2023/20242.054 154 340 64 283 190 521 201 152 131 18 0 0
Totale 42.928